Arvinas (ARVN) Interest Expenses (2017 - 2021)
Arvinas (ARVN) posted quarterly Interest Expenses of $3.9 million for Q1 2026, down 66.95% year-over-year from $11.8 million in Q1 2025, and up 875.0% quarter-over-quarter from $400000.0 in Q4 2025.
Analysis
Arvinas (ARVN) Interest Expenses (2017 - 2021) Analysis & Trends
Arvinas' Interest Expenses history runs 10 years deep, the most recent figure standing at $3.9 million for Q1 2026.
- In Q1 2026, Interest Expenses fell 66.95% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $3.9 million (down 66.95% YoY), while the FY2025 annual figure was $481.4 million, up 2.12% from the prior year.
- Interest Expenses for Q1 2026 stood at $3.9 million, up from $400000.0 in the prior quarter.
- The five-year high for Interest Expenses was $11.8 million in Q1 2025, with the low at $400000.0 in Q4 2025.
- The 5-year median for Interest Expenses is $2.5 million (2025), against an average of $3.1 million.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses tumbled 99.75% in 2022, then surged 640.0% in 2023.
- Arvinas' Interest Expenses stood at $2.2 million in 2022, then plunged by 77.27% to $500000.0 in 2023, then surged by 260.0% to $1.8 million in 2024, then tumbled by 77.78% to $400000.0 in 2025, then surged by 875.0% to $3.9 million in 2026.
- Business Quant data shows ARVN's Interest Expenses at $3.9 million in Q1 2026, $400000.0 in Q4 2025, and $2.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Arvinas | 609.77 Mn | 41.87 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 67,500.00 |
| Sep 30, 2021 | 8,125.00 |
| Jun 30, 2021 | 8,125.00 |
| Mar 31, 2021 | 16,250.00 |
| Dec 31, 2020 | 51,250.00 |
| Sep 30, 2020 | 16,250.00 |
| Jun 30, 2020 | 16,250.00 |
| Mar 31, 2020 | 16,250.00 |
| Dec 31, 2019 | 16,250.00 |
| Sep 30, 2019 | 22,903.00 |
| Jun 30, 2019 | 22,778.00 |
| Mar 31, 2019 | 23,638.00 |
| Dec 31, 2018 | 24,636.00 |
| Sep 30, 2018 | 12,264.00 |
| Jun 30, 2018 | 9,871.00 |
| Mar 31, 2018 | 10,669.00 |
| Dec 31, 2017 | 11,451.00 |
| Sep 30, 2017 | 12,219.00 |
| Jun 30, 2017 | 12,973.00 |
| Mar 31, 2017 | 13,713.00 |